ZA983602B - Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination - Google Patents
Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelinationInfo
- Publication number
- ZA983602B ZA983602B ZA983602A ZA983602A ZA983602B ZA 983602 B ZA983602 B ZA 983602B ZA 983602 A ZA983602 A ZA 983602A ZA 983602 A ZA983602 A ZA 983602A ZA 983602 B ZA983602 B ZA 983602B
- Authority
- ZA
- South Africa
- Prior art keywords
- drugs
- diseases
- preparation
- treatment
- tetrahydropyridine derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9705275A FR2762514B1 (fr) | 1997-04-29 | 1997-04-29 | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA983602B true ZA983602B (en) | 1998-11-02 |
Family
ID=9506415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA983602A ZA983602B (en) | 1997-04-29 | 1998-04-29 | Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination |
Country Status (18)
Country | Link |
---|---|
US (1) | US6344464B1 (xx) |
EP (1) | EP0979079B1 (xx) |
JP (1) | JP3956059B2 (xx) |
AR (1) | AR012504A1 (xx) |
AT (1) | ATE269077T1 (xx) |
AU (1) | AU7436498A (xx) |
BR (1) | BR9810234A (xx) |
CA (1) | CA2288241C (xx) |
DE (1) | DE69824576T2 (xx) |
DK (1) | DK0979079T3 (xx) |
ES (1) | ES2222593T3 (xx) |
FR (1) | FR2762514B1 (xx) |
NO (1) | NO325163B1 (xx) |
PT (1) | PT979079E (xx) |
SI (1) | SI0979079T1 (xx) |
UY (1) | UY24973A1 (xx) |
WO (1) | WO1998048802A1 (xx) |
ZA (1) | ZA983602B (xx) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2763847B1 (fr) * | 1997-05-28 | 2003-06-06 | Sanofi Sa | Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1 |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
FR2823748B1 (fr) * | 2001-04-20 | 2004-02-20 | Sanofi Synthelabo | Tetrahydropyridyl-alkyl-benzodiazines, procede pour leur preparation et compositions pharmaceutiques les contenant |
EP1383762B1 (fr) * | 2001-04-20 | 2007-06-20 | Sanofi-Aventis | Tetrahydropyridyl-alkyl-heterocycles, procede pour leur preparation et compositions pharmaceutiques les contenants |
US6886964B2 (en) * | 2001-06-26 | 2005-05-03 | Allan Gardiner | Illuminator with filter array and bandwidth controller |
NZ530765A (en) | 2001-06-26 | 2006-11-30 | Amgen Fremont Inc | Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases |
FR2831166B1 (fr) * | 2001-10-18 | 2004-02-27 | Sanofi Synthelabo | Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant |
MXPA05002514A (es) | 2002-09-06 | 2005-05-27 | Amgen Inc | Anticuerpo monoclonal anti-il-1r1 humano terapeutico. |
JP2006517191A (ja) * | 2002-12-30 | 2006-07-20 | アムジエン・インコーポレーテツド | 共刺激因子を用いた併用療法 |
US7838522B2 (en) | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
DK1828160T3 (da) | 2004-12-21 | 2012-02-13 | Merck Serono Sa | Cykliske sulfonylaminoderivater og anvendelse deraf som MMP-hæmmere |
JP4950070B2 (ja) | 2005-01-31 | 2012-06-13 | メルク セローノ ソシエテ アノニム | N−ヒドロキシアミド誘導体及びその使用 |
SI1904048T1 (sl) * | 2005-07-15 | 2012-01-31 | Merck Serono Sa | Inhibitorji glepp-1 pri zdravljenju avtoimunskih in/ali vnetnih obolenj |
BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 jnk 억제제 |
EP1933860A2 (en) | 2005-09-01 | 2008-06-25 | Ares Trading S.A. | Treatment of optic neuritis |
JP2011504505A (ja) * | 2007-11-21 | 2011-02-10 | デコード ジェネティクス イーエイチエフ | 肺および心血管障害を治療するためのビアリールpde4抑制剤 |
KR101707597B1 (ko) * | 2010-12-07 | 2017-02-17 | 한국전자통신연구원 | 홀 센서리스 bldc 모터용 전원 공급 모듈 |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
WO2023118544A1 (en) | 2021-12-23 | 2023-06-29 | Cilcare Dev | 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2531707A1 (fr) | 1982-08-16 | 1984-02-17 | Midy Spa | Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques |
FR2662355B1 (fr) | 1990-05-22 | 1994-11-10 | Sanofi Sa | Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux. |
HU211019B (en) * | 1991-12-02 | 1995-09-28 | Richter Gedeon Vegyeszet | Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds |
FR2736053B1 (fr) * | 1995-06-28 | 1997-09-19 | Sanofi Sa | Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines |
FR2740343B1 (fr) * | 1995-10-26 | 1999-01-22 | Sanofi Sa | Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique |
-
1997
- 1997-04-29 FR FR9705275A patent/FR2762514B1/fr not_active Expired - Fee Related
-
1998
- 1998-04-17 AT AT98921552T patent/ATE269077T1/de not_active IP Right Cessation
- 1998-04-17 WO PCT/FR1998/000774 patent/WO1998048802A1/fr active IP Right Grant
- 1998-04-17 DE DE69824576T patent/DE69824576T2/de not_active Expired - Fee Related
- 1998-04-17 DK DK98921552T patent/DK0979079T3/da active
- 1998-04-17 EP EP98921552A patent/EP0979079B1/fr not_active Expired - Lifetime
- 1998-04-17 SI SI9830677T patent/SI0979079T1/xx unknown
- 1998-04-17 ES ES98921552T patent/ES2222593T3/es not_active Expired - Lifetime
- 1998-04-17 JP JP54664898A patent/JP3956059B2/ja not_active Expired - Fee Related
- 1998-04-17 BR BR9810234-6A patent/BR9810234A/pt not_active Application Discontinuation
- 1998-04-17 US US09/403,507 patent/US6344464B1/en not_active Expired - Fee Related
- 1998-04-17 AU AU74364/98A patent/AU7436498A/en not_active Abandoned
- 1998-04-17 CA CA002288241A patent/CA2288241C/en not_active Expired - Fee Related
- 1998-04-17 PT PT98921552T patent/PT979079E/pt unknown
- 1998-04-23 UY UY24973A patent/UY24973A1/es not_active Application Discontinuation
- 1998-04-27 AR ARP980101935A patent/AR012504A1/es unknown
- 1998-04-29 ZA ZA983602A patent/ZA983602B/xx unknown
-
1999
- 1999-10-27 NO NO19995245A patent/NO325163B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
NO995245D0 (no) | 1999-10-27 |
CA2288241A1 (en) | 1998-11-05 |
JP3956059B2 (ja) | 2007-08-08 |
DK0979079T3 (da) | 2004-10-25 |
SI0979079T1 (en) | 2004-10-31 |
NO325163B1 (no) | 2008-02-11 |
NO995245L (no) | 1999-12-27 |
ATE269077T1 (de) | 2004-07-15 |
FR2762514B1 (fr) | 1999-10-22 |
FR2762514A1 (fr) | 1998-10-30 |
ES2222593T3 (es) | 2005-02-01 |
US6344464B1 (en) | 2002-02-05 |
BR9810234A (pt) | 2000-09-19 |
CA2288241C (en) | 2006-10-03 |
EP0979079B1 (fr) | 2004-06-16 |
AU7436498A (en) | 1998-11-24 |
PT979079E (pt) | 2004-10-29 |
DE69824576D1 (de) | 2004-07-22 |
AR012504A1 (es) | 2000-10-18 |
WO1998048802A1 (fr) | 1998-11-05 |
UY24973A1 (es) | 1998-07-16 |
DE69824576T2 (de) | 2005-06-30 |
EP0979079A1 (fr) | 2000-02-16 |
JP2002501498A (ja) | 2002-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA983602B (en) | Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination | |
IL147217A0 (en) | New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain | |
IL125735A0 (en) | Pharmaceutical compositions for the treatment of glaucoma | |
IL127714A0 (en) | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic depressive bipolar disorders | |
AU4048295A (en) | Peptide medicaments for the treatment of disease | |
AU2039800A (en) | 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins | |
HUP9900886A3 (en) | Use of bisphosphonates preventing bone loss associated with immunosuppressive therapy for the preparation of pharmaceutical compositions | |
GB2311940B (en) | Pharmaceutical compositions for the treatment of rhinitis | |
HUP9904317A3 (en) | Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases | |
HUP0104963A3 (en) | Compositions for the treatment of skin diseases | |
AU3684395A (en) | Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases | |
AU2739497A (en) | Use of vitamin d analogs for the treatment of arthritic disease | |
IL121096A0 (en) | Pharmaceutical compositions for the treatment of liver disease | |
IL120005A0 (en) | Pharmaceutical compositions for the treatment of the eye | |
IL121647A0 (en) | Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate | |
HUP0003159A3 (en) | The use of n-monosubstituted-3-oxo-4-aza-5alpha-androst-1-en-17betha-carboxamides for the preparation of pharmaceutical compositions | |
IL109235A0 (en) | Pharmaceutical compositions containing ureido derivatives for the treatment of lentivirus-induced diseases | |
IL135171A0 (en) | Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye | |
HUP0000569A3 (en) | Use of equilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states | |
HUP9801985A3 (en) | Use of cystine derivatives for the preparation of pharmaceutical compositions useful for the treatment of restenosis | |
ZA945651B (en) | Use of benzenesulphonzlindole derivatives for the preparation of medicines | |
GC0000176A (en) | Pharmaceutical combination preparations for the treatment of cardiac disorders | |
KR100248098B1 (en) | Pharmaceutical composition for the treatment of dementia | |
HUP0000570A3 (en) | Use of 17 alpha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states | |
HUP9903735A3 (en) | Use of indazolo derivatives for producing pharmaceutical compositions for treatment heart failure |